Kolexia
Ades Lionel Hématologie
Ades Lionel
Hématologie
Hôpital Saint-Louis
Paris, France
503 Activités
522 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Syndromes myélodysplasiques Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Leucémie myélomonocytaire chronique Leucémie aiguë promyélocytaire Préleucémie Anémie Maladies auto-immunes

Collaborateurs

Voir plus
Fenaux Pierre
Fenaux Pierre
Hôpital Saint-Louis, Paris, France
Raffoux Emmanuel
Raffoux Emmanuel
Hôpital Saint-Louis, Paris, France
Itzykson Raphael
Itzykson Raphael
Hôpital Saint-Louis, Paris, France
Sebert-Lesaignoux Marie
Sebert-Lesaignoux Marie
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
Novartis
31 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
26 collaboration(s)
Dernière en 2022
Abbvie
21 collaboration(s)
Dernière en 2023
Menarini
4 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes: A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Essai Clinique (Keros Therapeutics, Inc.)   11 mars 2024
National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
Essai Clinique (Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH)   22 février 2024
Germline CHEK2 mutations in patients with myeloid neoplasms.
Leukemia   20 février 2024
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
Leukemia   17 février 2024
IMpress: A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients With HR Myelodysplastic Syndromes or AML Failing HMA-based Therapy
Essai Clinique (GCP-Service International West GmbH)   05 février 2024
(MDS): A Phase II, Open-label, Multicenter Study of Orally Administered RVU120 for the Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms (MDS)
Essai Clinique (GCP-Service International West GmbH)   02 février 2024
PANTHER: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Essai Clinique (Takeda Pharmaceutical)   04 janvier 2024
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA: A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Essai Clinique (Celgene)   02 janvier 2024
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M.
Blood cancer journal   21 décembre 2023
Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes.
Cancer treatment reviews   19 décembre 2023